COMMUNIQUÉS West-GlobeNewswire

Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
18/05/2026
Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license Phase 1 initiation for CT-202 trial expected in third quarter of 2026 PHILADELPHIA, May 18, 2026 [...]
Kraig Biocraft Laboratories Announces Breakthrough Creation of Immortalized Silkworm Silk Gland Cell Line with Broad Biotechnology Applications
18/05/2026
ANN ARBOR, Mich., May 18, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced a biotechnology [...]
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
18/05/2026
FLORHAM PARK, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other [...]
BrainsWay Announces Minority-Stake Investment in Hopemark Health
18/05/2026
Investment in provider servicing clinics in Illinois is latest in series of similar transactions by BrainsWay with leading North American mental health providers to raise awareness and expand access to transformative [...]
Byondis Establishes Scientific Advisory Board of Recognized Leaders in Oncology Research and ADC Development
18/05/2026
Global experts in antibody-drug conjugate (ADC) development, oncology clinical development and early-phase trial design, appointed to support advancement of Byondis’ differentiated ADC pipeline and a new generation of [...]
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
18/05/2026
Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological [...]
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update
18/05/2026
Key highlights from the first quarter of operations under the expanded management team include the following: Anticipated FDA decision on the Company's ANDA for Preservative-Free Ketamine in Q3 2026, with favorable [...]
Vincentage Pharma Reports Positive Top-Line Results from Pivotal Phase 3 Trial of VCT220 in Obese or Overweight Chinese Adults
18/05/2026
CHENGDU, China, May 18, 2026 (GLOBE NEWSWIRE) -- Vincentage Pharma Co., Ltd. (the “Company”) today announced positive top-line results from the Company’s pivotal Phase 3 trial evaluating its internally discovered, [...]
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
18/05/2026
Completed successful FDA End-of-Phase 2 meeting, reaching alignment on the study parameters of RESTORE, a registrational study of NVG-291 in chronic tetraplegia, with site activation underway and study initiation on [...]
GMR Solutions Inc. Announces Ratings Upgrade and Debt Reduction
18/05/2026
Post-IPO rating improvement from S&P Global Ratings and Moody’s Ratings LEWISVILLE, Texas, May 18, 2026 (GLOBE NEWSWIRE) -- GMR Solutions Inc. (NYSE: GMRS) and its wholly owned subsidiary Global Medical Response, [...]
JASCAYD® (nerandomilast) approved in Japan, advancing global access to a new IPF and PPF treatment
18/05/2026
Not intended for UK and US audiences JASCAYD ® (nerandomilast) now approved by Japan’s MHLW for the treatment of adults with idiopathic pulmonary fibrosis and adults with progressive pulmonary fibrosis Approval enables [...]
Cytovation to Evaluate Getacatetide (CY-101) in Combination with Checkpoint Inhibitor Tislelizumab in Colorectal Cancer
18/05/2026
Phase 2 study to evaluate combination therapy in patients with metastatic colorectal cancer, targeting β-catenin-driven immune exclusion in liver metastases BeOne Medicines to supply tislelizumab (a PD-1 inhibitor) for [...]
Philips to deliver vital technology for hospital-at-home care for up to 15,000 patients annually in Region Stockholm
18/05/2026
May 18, 2026 Philips-led consortium selected through Karolinska University Hospital-led Region Stockholm tender to deliver advanced remote monitoring for complex patients Stockholm, Sweden - Royal Philips (NYSE: PHG, [...]
Byondis Establishes Scientific Advisory Board of Recognized Leaders in Oncology Research and ADC Development
18/05/2026
Global experts in antibody-drug conjugate (ADC) development, oncology clinical development and early-phase trial design, appointed to support advancement of Byondis’ differentiated ADC pipeline and a new generation of [...]
NovalGen Appoints Dr Laurent Fischer as Chair of the Board
18/05/2026
LONDON, May 18, 2026 (GLOBE NEWSWIRE) -- NovalGen today announced the appointment of Dr Laurent Fischer, a globally recognized biopharmaceutical executive, as Non-Executive Chair of the Board of Directors with immediate [...]
Ipsen lance un nouveau programme de rachat d’actions
18/05/2026
Ipsen lance un nouveau programme de rachat d’actions PARIS, FRANCE, 18 MAI 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) annonce aujourd'hui avoir confié à un prestataire de services d’investissement un mandat à l’effet de [...]
Ipsen initiates a new share buy-back program
18/05/2026
Ipsen initiates a new share buy-back program PARIS, FRANCE, 18 MAY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it has appointed an investment services provider to purchase an aggregate number of up to [...]
AVITA Medical to Host Investor Webinar Briefing
18/05/2026
VALENCIA, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective [...]
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer
17/05/2026
More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC alone Deep PSA reduction higher in patients receiving Pluvicto combination vs. SoC at 12, 24 and 48 weeks [...]

Pages